CN102203084B - 盐酸尼洛替尼晶型 - Google Patents

盐酸尼洛替尼晶型 Download PDF

Info

Publication number
CN102203084B
CN102203084B CN200980144606.XA CN200980144606A CN102203084B CN 102203084 B CN102203084 B CN 102203084B CN 200980144606 A CN200980144606 A CN 200980144606A CN 102203084 B CN102203084 B CN 102203084B
Authority
CN
China
Prior art keywords
nilotinib
nilotinib hydrochloride
degrees
powder diffraction
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980144606.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102203084A (zh
Inventor
G·斯特里姆鲍姆
S·莱维
A·约里
T·科尔泰
V·尼达姆-希尔德舍伊姆
M·皮兰
S·阿西斯
H·埃森-内沃
D·M·克罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102203084(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN102203084A publication Critical patent/CN102203084A/zh
Application granted granted Critical
Publication of CN102203084B publication Critical patent/CN102203084B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Exhaust Gas Treatment By Means Of Catalyst (AREA)
CN200980144606.XA 2008-11-05 2009-11-05 盐酸尼洛替尼晶型 Active CN102203084B (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US11156108P 2008-11-05 2008-11-05
US61/111561 2008-11-05
US15578909P 2009-02-26 2009-02-26
US61/155789 2009-02-26
US17745409P 2009-05-12 2009-05-12
US61/177454 2009-05-12
US22721009P 2009-07-21 2009-07-21
US61/227210 2009-07-21
US24070909P 2009-09-09 2009-09-09
US61/240709 2009-09-09
US24251409P 2009-09-15 2009-09-15
US61/242514 2009-09-15
US24679909P 2009-09-29 2009-09-29
US61/246799 2009-09-29
US24937609P 2009-10-07 2009-10-07
US61/249376 2009-10-07
PCT/US2009/063365 WO2010054056A2 (en) 2008-11-05 2009-11-05 Nilotinib hci crystalline forms

Publications (2)

Publication Number Publication Date
CN102203084A CN102203084A (zh) 2011-09-28
CN102203084B true CN102203084B (zh) 2014-10-29

Family

ID=41666779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980144606.XA Active CN102203084B (zh) 2008-11-05 2009-11-05 盐酸尼洛替尼晶型

Country Status (12)

Country Link
US (2) US8227477B2 (enExample)
EP (2) EP2530081A3 (enExample)
JP (1) JP5486012B2 (enExample)
KR (2) KR20120111743A (enExample)
CN (1) CN102203084B (enExample)
CA (1) CA2740794A1 (enExample)
DK (1) DK2262793T3 (enExample)
ES (1) ES2394258T3 (enExample)
HR (1) HRP20120793T1 (enExample)
PL (1) PL2262793T3 (enExample)
TW (1) TW201022240A (enExample)
WO (1) WO2010054056A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2010KO00035A (enExample) * 2010-01-15 2016-09-02
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
CN103038227A (zh) * 2010-06-21 2013-04-10 特瓦制药工业有限公司 尼洛替尼盐及其晶形
HRP20151324T1 (hr) 2010-06-21 2016-01-29 Teva Pharmaceutical Industries, Ltd. Soli nilotiniba i njihovi kristalni oblici
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
IN2011CH01887A (enExample) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CA2888002A1 (en) * 2012-10-15 2014-04-24 Apotex Inc. Solid forms of nilotinib hydrochloride
MX2015004947A (es) * 2012-10-19 2016-02-22 Basf Se Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados.
NZ714378A (en) 2013-04-24 2020-08-28 Dr Reddys Laboratories Ltd Polymorphic forms of nilotinib hydrochloride
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
CN106478603B (zh) * 2015-08-25 2021-01-01 江苏豪森药业集团有限公司 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
HUE050890T2 (hu) 2016-03-14 2021-01-28 Pliva Hrvatska D O O Nilotinib sók szilárd halmazállapotú formái
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
US20240316044A1 (en) 2021-06-19 2024-09-26 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228150A (zh) * 2005-07-20 2008-07-23 诺瓦提斯公司 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
FR2889524B1 (fr) 2005-08-05 2008-08-29 Rhodia Chimie Sas Procede de formation d'une liaison carbone-azote
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228150A (zh) * 2005-07-20 2008-07-23 诺瓦提斯公司 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形

Also Published As

Publication number Publication date
HRP20120793T1 (hr) 2012-12-31
US8227477B2 (en) 2012-07-24
KR101251726B1 (ko) 2013-04-05
EP2262793A2 (en) 2010-12-22
US20130096304A1 (en) 2013-04-18
EP2262793B1 (en) 2012-10-03
KR20120111743A (ko) 2012-10-10
PL2262793T3 (pl) 2013-01-31
WO2010054056A2 (en) 2010-05-14
EP2530081A2 (en) 2012-12-05
US20100190812A1 (en) 2010-07-29
JP5486012B2 (ja) 2014-05-07
EP2530081A3 (en) 2013-04-10
JP2012508178A (ja) 2012-04-05
CN102203084A (zh) 2011-09-28
US8592442B2 (en) 2013-11-26
KR20100099257A (ko) 2010-09-10
DK2262793T3 (da) 2012-10-15
ES2394258T3 (es) 2013-01-30
WO2010054056A3 (en) 2010-09-16
CA2740794A1 (en) 2010-05-14
TW201022240A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CN102203084B (zh) 盐酸尼洛替尼晶型
US11292793B2 (en) Solid dispersions of amorphous Lumateperone p-Tosylate
CN101959856A (zh) 来那度胺的制备
TWI849043B (zh) B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
CN117545755A (zh) 一种Lanifibranor的晶型及其制备方法
WO2009146325A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
CN102471273B (zh) 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法
CN110944979B (zh) Odm-201晶型及其制备方法和药物组合物
WO2009053840A2 (en) Solid forms of (±)-o-desmethylvenlafaxine salts
US20190300483A1 (en) POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
WO2022054096A1 (en) Solid forms of substituted polycyclic pyridone compounds and prodrugs therof and process of preparation thereof
WO2014016842A1 (en) Amorphous coprecipitates of rivaroxaban
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
WO2019210511A1 (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
WO2018134843A1 (en) Polymorphic forms of (e)-n-{4-[3-chloro-4-((pyridin-2-yl methoxy)anilino]-3-cyano-7- ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, its maleate salt and process for preparation thereof
WO2017115315A1 (en) Solid forms of palbociclib
US20220389022A1 (en) Solid forms of ponatinib hydrochloride and process thereof
CN102239163A (zh) 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
EP2225224A2 (en) Novel hemioxalate salt of eletriptan
WO2018049634A1 (zh) Abt-199加成盐及其晶型、其制备方法和药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant